Mesa Laboratories Inc (MLAB) valuation
Mesa Laboratories P/E ratio history
Mesa Laboratories trades at 150.4 times its earnings over the last twelve months and 12.7 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 42.2 (year to Mar 2017) to 481.0 (year to Mar 2020), with a median of 123.9.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Mar 31, 2026 | $88.42 | $1.21 | 73.1 |
| Mar 31, 2025 | $118.66 | -$0.36 | n/m |
| Mar 31, 2024 | $109.73 | -$47.20 | n/m |
| Mar 31, 2023 | $174.73 | $0.17 | n/m |
| Mar 31, 2022 | $254.88 | $0.35 | n/m |
| Mar 31, 2021 | $243.50 | $0.62 | 392.7 |
| Mar 31, 2020 | $226.09 | $0.47 | 481.0 |
| Mar 31, 2019 | $230.50 | $1.86 | 123.9 |
| Mar 31, 2018 | $148.44 | -$0.86 | n/m |
| Mar 31, 2017 | $122.70 | $2.91 | 42.2 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Mesa Laboratories valuation against its peers
| Company | Market value | Price / sales |
|---|---|---|
| Mesa LaboratoriesMLAB | $706M | 2.8 |
| Wave Life SciencesWVE | $707M | 10.0 |
| Sana BiotechnologySANA | $715M | — |
| Jade BiosciencesJBIO | $694M | — |
| Arrivent BiopharmaAVBP | $693M | — |
| Ginkgo Bioworks Holdings Inc ClassDNA | $732M | 6.5 |
| OmniabOABI | $741M | 19.3 |
| Design TherapeuticsDSGN | $667M | — |
| ArdelyxARDX | $748M | 1.7 |
| Peer median | 8.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: MLAB financials · MLAB returns
No forecast, no recommendation. This page describes Mesa Laboratories Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.